Published in Vaccine Weekly, August 10th, 1998
"Given the rapid global increase in tuberculosis and the widespread use of bacillus Calmette-Guerin (BCG), there is a remarkable paucity of recent data regarding the basic immune response to BCG in human populations," researcher Philip W. Lowry and colleagues wrote ("Cellular Immune Responses to Four Doses of Percutaneous Bacille Calmette-Guerin in Healthy Adults," The Journal of Infectious Diseases, July 1998;178:138-146).
"Additional studies are needed, particularly given the emerging interest in utilizing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.